Previous close | 11.50 |
Open | 11.40 |
Bid | 11.97 x 200 |
Ask | 12.04 x 100 |
Day's range | 11.40 - 12.14 |
52-week range | 9.76 - 56.37 |
Volume | |
Avg. volume | 1,187,819 |
Market cap | 722.184M |
Beta (5Y monthly) | 0.92 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The phase II SURVEYOR study evaluating SAGE's dalzanemdor as a potential treatment for patients with cognition dysfunction caused by Huntington's disease meets its primary endpoint.
Investing.com - Baird Equity Research has initiated coverage of SAGE Therapeutics Inc (NASDAQ:SAGE), assigning it a neutral rating with a price target of $15.
In this article, we will be taking a look at the 15 most depressed states in the US. If you are not interested in learning about the global and regional trends in the depression treatment market, head straight to the 5 Most Depressed States in the US. Global and Regional Trends in the Depression Treatment […]